Sanofi: positive data in atopic dermatitis
(CercleFinance.com) - Sanofi today reports positive results from the clinical trial of Dupixent (dupilumab) in the treatment of uncontrolled moderate-to-severe atopic dermatitis of hands and feet in adults and adolescents.
Late-breaking data presented at the American Academy of Dermatology (AAD) meeting showed significant improvements in the signs and symptoms of this disease, meeting both the study's primary and secondary endpoints.
More than twice as many patients treated with Dupixent showed clear or almost clear skin at 16 weeks, compared to placebo, Sanofi said.
Nearly four times as many Dupixent-treated patients showed a clinically significant decrease in itching, with improvements observed as early as the first week of treatment.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Late-breaking data presented at the American Academy of Dermatology (AAD) meeting showed significant improvements in the signs and symptoms of this disease, meeting both the study's primary and secondary endpoints.
More than twice as many patients treated with Dupixent showed clear or almost clear skin at 16 weeks, compared to placebo, Sanofi said.
Nearly four times as many Dupixent-treated patients showed a clinically significant decrease in itching, with improvements observed as early as the first week of treatment.
Copyright (c) 2023 CercleFinance.com. All rights reserved.